The deal is a new sublease for the biopharmaceutical firm, which relocated to a smaller space in the Durst-owned tower via a ...

AXS-12, known as reboxetine back when it was available as an antidepressant in the United States, may decrease cataplexy ...

President Donald Trump launched a barrage of steep tariffs, dubbing it “Liberation Day” and igniting a full-scale trade war ...

If you know someone battling depression or Alzheimer’s, Dr. Herriot Tabuteau might just become your new hero. For years, ...

Continued treatment with AXS-05, a combination of dextromethorphan and bupropion, significantly reduces the risk for recurrence of Alzheimer’s disease–related agitation, phase 3 results show.

At the recent American Academy of Neurology (AAN) 2025 annual meeting, Axsome Therapeutics (Nasdaq: AXSM) presented promising data for AXS-05 (bupropion + dextromethorphan) in treating agitation ...

Oral triptans are considered the industry gold standard acute treatments and there are currently seven approved, all with ...

Agitated patients are often prescribed antipsychotic medications and sedatives off-label, but this can pose a risk to the ...

Axsome Therapeutics, Inc.’s AXSM share price has dipped by 8.23%, which has investors questioning if this is right time to ...

AXS-05 was well-tolerated and significantly delayed the time to agitation relapse compared with placebo in patients with ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...